pSivida Reveals Follow-Up Data on Durasert Trial

pSivida (NASDAQ:PSDV, ASX:PVA) announced positive data from a 12-month follow-up on the company’s three-year treatment for posterior segment uveitis with Durasert.
As quoted in the press release:

The data is from the Company’s first Phase 3 trial.

• Durasert three-year uveitis implant demonstrated a significant reduction in the recurrence of posterior segment uveitis through 12 months.

• 27.6% of Durasert treated patients had a recurrence compared to 85.7% of patients in the sham group (p<0.001).

• The Best Corrected Visual Acuity (BCVA) gain of 15 letters or more at six and 12 months was 23% and 22.4%, respectively, for Durasert and 7.3% and 10.3%, respectively, for sham, demonstrating sustained effect over 12 months.

• Intraocular pressure (IOP) elevation, which can lead to glaucoma, at 12 months was 1.3mm mean for Durasert vs 0.2mm mean for sham. Patients requiring IOP-lowering therapy at 12 months were 26.4% for Durasert and 26.2% for sham.

• In phakic patients at baseline, 33.3% in the Durasert group required a cataract surgery through 12 months compared to 4.8% in the sham group; Phakic refers to patients with a natural lens vs those who have had cataract lens replacement surgery.

Click here to read the full press release.

Source: globenewswire.com